Early Glycemic Control With Metformin Cuts CVD Events

This article originally appeared here.
Share this content:
Early Glycemic Control With Metformin Cuts CVD Events
Early Glycemic Control With Metformin Cuts CVD Events

FRIDAY, April 21, 2017 (HealthDay News) -- For patients with type 2 diabetes who initiate metformin, early achievement of low hemoglobin A1c (HbA1c) is associated with a reduction in the subsequent risk of cardiovascular events or death, according to a study published online April 12 in Diabetes Care.

Elisabeth Svensson, Ph.D., from Aarhus University Hospital in Denmark, and colleagues conducted a population-based study involving 24,572 metformin initiators with HbA1c tests in Northern Denmark from 2000 to 2012 (median follow-up, 2.6 years). Patients were classified by HbA1c achieved at six months after metformin initiation and by the magnitude of change in HbA1c from the pretreatment base.

The researchers found that, compared with a target HbA1c of <6.5 percent, the risk of a combined outcome event (acute myocardial infarction, stroke, or death) increased gradually with increasing levels of HbA1c achieved (adjusted hazard ratios, 1.18 for 6.5 to 6.99 percent; 1.23 for 7.0 to 7.49 percent; 1.34 for 7.5 to 7.99 percent, and 1.59 for ≥8 percent). Outcome was also predicted by a large absolute HbA1c reduction from baseline (adjusted hazard ratio, 0.80 for Δ = −4, compared with no change [Δ = 0]).

"A large initial HbA1c reduction and achievement of low HbA1c levels within six months after metformin initiation are associated with a lower risk of cardiovascular events and death in patients with type 2 diabetes," the authors write.

Several authors disclosed financial ties to Novo Nordisk, which partially funded the study.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Panel Has Tie Vote on New Type 1 Diabetes Drug

FDA Panel Has Tie Vote on New Type ...

Zynquista is a once-daily pill meant to help type 1 diabetes patients manage their blood glucose levels

FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents

FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents

Investigation triggered by meta-analysis showing possible increased mortality in PAD patients at 2 years

Frailty Could Increase Susceptibility for Dementia

Frailty Could Increase Susceptibility for Dementia

Authors say frailty should be considered in clinical care, management of Alzheimer dementia

is free, fast, and customized just for you!




Already a member?

Sign In Now »